Market Overview

Thoratec Corp Does not Expect FDA Letter will Materially Impact Company's Financials

Share:

Thoratec Corporation (NASDAQ: THOR) received a Warning Letter from the U.S. Food and Drug Administration on January 4, 2012. The Warning Letter relates to the late filing of two Medical Device Reports by Thoratec, which were originally discussed in a Form 483 issued by FDA after an inspection of the Company's California manufacturing facilities in August and September 2011. The Company takes these matters seriously and expects to respond to the FDA's requests within the required time frame. Following the receipt of the Form 483, we provided written responses to the FDA detailing proposed preventive and corrective actions and immediately initiated efforts to address FDA's observations. The FDA Warning Letter indicates that, with respect to the Form 483 observations unrelated to MDRs, Thoratec's responses provided during and after the inspection appeared to be adequate. The Company believes that the FDA's concerns set forth in the Warning Letter can be resolved without a material impact to the Company's financial results. In particular, we do not expect either customer orders or our ability to manufacture or ship products to be impacted by the Warning Letter.

View filing here.

Posted-In: News FDA

 

Related Articles (THOR)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Amerigroup Announces Pricing of $75 Million of 7.50% Senior Notes Due 2019

UPDATE: ADM to End Commercial Alliance with Metabolix